Genesis Study

by Eclat srl · Medical · Free

On the App Store since September 2021 · Data updated 2026-10-28

Genesis Study is made and published by Eclat srl. AppBrain is an independent app data site and isn't affiliated with Eclat srl. The app name, icon, screenshots and description belong to Eclat srl and are shown as published on the App Store.

AppBrain's verdict

Last updated: January 31, 2025

Official page on the App Store

Rankings

App Store top charts

App Store Rankings for Genesis Study

This app is not ranked

Competitors

Similar apps and more from Eclat srl

Alternatives to Genesis Study

Releases

Updates seen on the App Store

Version: 1.0.12
Launched: September 2021

No changelog data

User feedback

Ratings and reviews on the App Store

Comments on Genesis Study for iOS

We don't have enough comments to show example comments. Please check back later.

Technology

Found in the app by AppBrain

Price: Free
App size: 32.7 MB
Content rating: High

Technologies used by Genesis Study

About the app and developer

About Genesis Study

Genesis Study is a medical app developed by Eclat srl.

User Ratings

The app has no ratings yet.

App Information

Genesis Study is freely available from the App Store. The app size is 32.69 MB. The latest version available is 1.0.12. The last update was on January 31, 2025.

Technical Requirements

The app has a content rating of High Maturity. The app has been available on the App Store since September 2021.

Developer information for Eclat srl

Eclat srl

Address:

Store listing

By Eclat srl, from the App Store

Screenshots by Eclat srl, from the the App Store listing

Description by Eclat srl Written by the developer, not by AppBrain. Click to read.

A 12-month randomised, double-blind, controlled, international multicentre trial comparing changes in cigarette consumption after switching to high or low nicotine strength e-cigarettes in smokers with Schizophrenia spectrum disorders. This will be a multicenter, 12-months prospective trial, utilizing a randomized, double-blind, 2-arm parallel, switching design to compare effectiveness, tolerability, acceptability, and pattern of use between high (JUUL 5% nicotine) and low nicotine strength devices (JUUL 1.5% nicotine) in adult smokers with schizophrenia spectrum disorders. The study will take place at 5 sites: 1 in the UK (London) and possibly 4 in Italy.

DISCLAIMER : To seek a doctor’s advice in addition to using this app and before making any medical decisions.

We are using HealthKit to get step count to display on Health Dairy screen and graph on Report screen. We also send daily step count to server with questionary for study purpose.